the INFECTIOUS DISEASES channel
رفتن به کانال در Telegram
🌀The aim of this group is to make the Infectious Diseases and it’s related issues more logical and easy. 🌀Will try to share useful information in this fantastic field. 🌀Supervised by Dr. Alaa Alali Ⓜ️&🆔 🌀So, you are welcome 🙏🏻
نمایش بیشتر9 039
مشترکین
-224 ساعت
+87 روز
+8430 روز
در حال بارگیری داده...
کانالهای مشابه
ابر برچسبها
اشارات ورودی و خروجی
---
---
---
---
---
---
جذب مشترکین
سپتامبر '26
سپتامبر '26
+16
در 0 کانالها
اوت '26
+150
در 0 کانالها
Get PRO
ژوئیه '26
+223
در 0 کانالها
Get PRO
ژوئن '26
+112
در 0 کانالها
Get PRO
مه '26
+139
در 0 کانالها
Get PRO
آوریل '26
+139
در 0 کانالها
Get PRO
مارس '26
+99
در 0 کانالها
Get PRO
فوریه '26
+126
در 0 کانالها
Get PRO
ژانویه '26
+106
در 0 کانالها
Get PRO
دسامبر '25
+121
در 0 کانالها
Get PRO
نوامبر '25
+117
در 1 کانالها
Get PRO
اکتبر '25
+162
در 0 کانالها
Get PRO
سپتامبر '25
+218
در 0 کانالها
Get PRO
اوت '25
+200
در 0 کانالها
Get PRO
ژوئیه '25
+213
در 0 کانالها
Get PRO
ژوئن '25
+222
در 0 کانالها
Get PRO
مه '25
+195
در 0 کانالها
Get PRO
آوریل '25
+226
در 0 کانالها
Get PRO
مارس '25
+236
در 0 کانالها
Get PRO
فوریه '25
+246
در 0 کانالها
Get PRO
ژانویه '25
+354
در 0 کانالها
Get PRO
دسامبر '24
+338
در 0 کانالها
Get PRO
نوامبر '24
+318
در 0 کانالها
Get PRO
اکتبر '24
+299
در 0 کانالها
Get PRO
سپتامبر '24
+305
در 0 کانالها
Get PRO
اوت '24
+258
در 0 کانالها
Get PRO
ژوئیه '24
+111
در 0 کانالها
Get PRO
ژوئن '24
+100
در 0 کانالها
Get PRO
مه '24
+141
در 0 کانالها
Get PRO
آوریل '24
+105
در 0 کانالها
Get PRO
مارس '24
+101
در 0 کانالها
Get PRO
فوریه '24
+123
در 0 کانالها
Get PRO
ژانویه '24
+178
در 0 کانالها
Get PRO
دسامبر '23
+4 505
در 0 کانالها
| تاریخ | رشد مشترکین | اشارات | کانالها | |
| 05 سپتامبر | +6 | |||
| 04 سپتامبر | +1 | |||
| 03 سپتامبر | +4 | |||
| 02 سپتامبر | +2 | |||
| 01 سپتامبر | +3 |
پستهای کانال
+3🦠 Know the bug
⚙️ Know the mechanism
🧫 Check the susceptibility
🎯 Control the source
💊 Choose the narrowest effective therapy
💥 IDSA 2026. 🦠💊
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag481/8756906
| 2 | https://youtu.be/S33Mz6dks0k?si=Y6k36o5Ixv6ZCPZH | 499 |
| 3 |  https://jamanetwork.com/ | 764 |
| 4 | The latest international AIDS meeting took place in Rio de Janeiro highlights
https://voices.nejm.org/doi/full/10.1056/VOICESpost2600043?query=voices_ps&cid=DM2461488_&bid=-649123859 | 1 878 |
| 5 | Ask the Expert, focusing on the diagnosis and management of pyelonephritis in kidney transplant recipients.
https://www.tts.org/tid-education/tid-ask-the-expert | 2 457 |
| 6 | The curious case of thick-walled buds and a pink lung!
https://www.idimages.org/m/cases/viewfeatured/?caseid=625&fbclid=IwT01FWATj7GdwZG9mBWV4dG4DYWVtAjEwAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHqv45QzJRcxA3rL6FvwR46G1-rK6NKF1hLisW4WrGjj4KvhRhm5eAmnX5YN1_aem_uAsZ91Ag6pAML-7aQvFRJQ | 2 101 |
| 7 | Infections in Hematologic Malignancies and Stem Cell Transplantation
https://youtu.be/v0Vl7ui1mVQ?si=9L4jZRj9tY0_bW45 | 1 883 |
| 8 |  Dana M. Blyth; Clinton K. Murray
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 318, 3774-3781.e3 | 1 810 |
| 9 |  +6Source: Nix C, Bisht A. Infection Prevention in Oncology. In: APIC Text Online. Association for Professionals in Infection Control and Epidemiology (APIC); 2026. | 2 286 |
| 10 | 🦠 IDSA 2026 AMR Gram-Negative Guidance
What's New? | July 2026
🔵 ESBL-Producing Enterobacterales (ESBL-E)
🧪 New ESBL definition
Ceftriaxone MIC ≥4 µg/mL
💊 New agents added
✅ Gepotidacin
✅ Pivmecillinam
✅ Oral sulopenem
✅ IV fosfomycin
✅ Cefepime-enmetazobactam (emerging role)
📌 Practice update
Piperacillin-tazobactam may be considered for complicated UTI (not first choice for invasive disease).
---
🟢 AmpC-Producing Enterobacterales
🦠 New organism
Hafnia alvei added as moderate-risk AmpC producer.
📌 Key updates
Continue ceftriaxone if:
Non-severe infection
Clinical improvement
Adequate source control
⚠️ Piperacillin-tazobactam appears suboptimal for invasive AmpC infections.
---
🔴 Carbapenem-Resistant Enterobacterales (CRE)
⭐ Major advance
Aztreonam-avibactam introduced for NDM-producing CRE and is slightly preferred over ceftazidime-avibactam + aztreonam.
🆕 Added:
IV fosfomycin
Gepotidacin
Pivmecillinam
🔬 Updated comparisons:
Ceftazidime-avibactam vs Meropenem-vaborbactam
Aztreonam-avibactam vs Cefiderocol
---
🟣 Difficult-to-Treat (DTR) Pseudomonas aeruginosa
🏆 Preferred for uncomplicated UTI
Single-dose amikacin or tobramycin
🫁 Pneumonia
Ceftolozane-tazobactam preferred over ceftazidime-avibactam.
💨 Nebulised antibiotics:
Still not routinely recommended, but evidence is becoming more favourable.
---
🟠 Carbapenem-Resistant Acinetobacter baumannii (CRAB)
🥇 First-line therapy
Sulbactam-durlobactam + carbapenem
⏳ Alternative regimens:
Only as bridge therapy until sulbactam-durlobactam becomes available.
If resistant:
Two active non-sulbactam agents or
Sulbactam-durlobactam + cefiderocol
---
🟡 Stenotrophomonas maltophilia
⭐ Preferred therapy
Cefiderocol monotherapy
➕ Aztreonam-avibactam added as part of combination therapy for selected invasive infections.
---
🚨 Top 6 Take-Home Messages
✅ New FDA-approved antibiotics incorporated into guidance.
✅ Aztreonam-avibactam is now preferred for NDM-producing CRE.
✅ Sulbactam-durlobactam becomes the cornerstone of invasive CRAB treatment.
✅ Ceftolozane-tazobactam is favoured for DTR Pseudomonas pneumonia.
✅ Piperacillin-tazobactam has a limited role (acceptable for some complicated ESBL UTIs but generally not for invasive AmpC infections).
✅ Updated microbiology definitions and resistance epidemiology should guide antimicrobial stewardship and empiric therapy.
> Bottom line: The 2026 IDSA guidance expands therapeutic options, emphasises newer β-lactam/β-lactamase inhibitor combinations, refines laboratory interpretation, and strengthens precision treatment based on resistance mechanisms.
https://www.idsociety.org/practice-guideline/amr-guidance/ | 2 110 |
| 11 |  +2بدون متن... | 1 636 |
| 12 |  +1بدون متن... | 1 730 |
| 13 |  +1https://www.pha.gov.sa/ar-sa/Pages/default.aspx | 1 646 |
| 14 |  https://cidsupdate.cidsindia.org/all-books/68b6926e785095ca78382485?chapterId=68b69c5b785095ca78382e23 | 1 806 |
| 15 |  +3Latent TB pearls ✨️ | 2 391 |
| 16 |  +2بدون متن... | 2 017 |
| 17 |  +2بدون متن... | 2 119 |
| 18 |  Photo from Mohammed Alabdullah ID | 2 434 |
| 19 |  +1Management of Staphylococcus aureus bacteremia
https://www.idsociety.org/globalassets/idsa/practice-guidelines/sab/consensus-statement-7-manuscript.pdf | 2 447 |
| 20 |  +3بدون متن... | 2 254 |
